Survey

How are the Trump tariffs affecting you? Take our survey and let us know.

Cboe UK DKK

Genmab A/S (GMABC.XC)

1,295.25

0.00

(0.00%)

At close: April 22 at 10:30:17 AM GMT+1

No Tool

Measure

UNDO

Redo

All

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for GMABC.XC

Transactions in Connection with Share Buy-back Program

Transactions in Connection with Share Buy-back Program

GMAB or RGEN: Which Is the Better Value Stock Right Now?

GMAB or RGEN: Which Is the Better Value Stock Right Now?

Should Value Investors Buy Genmab (GMAB) Stock?

Should Value Investors Buy Genmab (GMAB) Stock?

Genmab (CPSE:GMAB) Reports US$3 Billion DARZALEX Sales For Q1 2025

Genmab (CPSE:GMAB) Reports US$3 Billion DARZALEX Sales For Q1 2025

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Genmab A/S Share Capital Reduction

Genmab A/S Share Capital Reduction

Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now?

Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now?

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Is Genmab A/S (GMAB) the Most Undervalued Healthcare Stock to Buy According to Analysts?

Is Genmab A/S (GMAB) the Most Undervalued Healthcare Stock to Buy According to Analysts?

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

This drug company’s silver bullet is currently valued at zero

This drug company’s silver bullet is currently valued at zero